Latest news

As an expert in SOS1/2 biology and tumorigenesis, I was pleased to see the opnMe call for novel hypotheses around SOS1::KRAS. It was the starting point that led to a productive research collaboration and now culminated into a high-profile publication.

opnMe helped us create a collaboration with a team at Boehringer that had designed an IDO inhibitor, leading to many fruitful interactions. It is a real team effort between my lab at Yale and the scientists at Boehringer. I am so hoping that this can lead to a true treatment for many patients.

The investigation of pancreatic islet regeneration has been central to my lab's research. My collaboration with Boehringer Ingelheim, mediated by its open innovation portal opnMe, has provided us with access to unique reagents and resources and enabled rapid progress over the past two years.

It has been a pleasure for me to participate in opnMe. In addition to providing funding for our research project, it has given my lab an opportunity to collaborate with excellent people at Boehringer Ingelheim, generated some exciting results, and taught us new things about brain circuitry.

opnMe facilitated an efficient research partnership with Boehringer Ingelheim, accelerating the discovery of bioactive peptides. opnMe enabled us to combine expertise and resources, therefore leveraging the strengths of both organizations to achieve innovative outcomes.

opnMe's expert guidance was pivotal in forging our research collaboration with Boehringer Ingelheim. Their initiative seamlessly bridged the gap between academic and industry research, uniting foundational biomedical science with application-oriented translational animal health research.

opnMe represents a great concept of open science in two ways: It allows Boehringer to stimulate research at the forefront of scientific discovery within a well-defined disease area and it allows academics to excel by approaching Boehringer Ingelheim with proactive, innovative ideas.

opnMe has allowed us to showcase the potential of our novel subcutaneous drug delivery platform. They provided clinically relevant "beyond the rule of 5" compounds, which we successfully formulated. Their expert input during meetings was invaluable in advancing the research towards solving challenges of difficult to formulate compounds.

As an academic postdoc, opnMe provided me with the opportunity to apply my skills in a "semi-industry" setting. Collaborating with Boehringer Ingelheim’s experts on pharmacologically relevant questions in neuroscience was particularly exciting, as it aligns with my deep passion for the field.

opnMe has been instrumental in advancing our research in retinal diseases by providing access to a unique compound for IL1RAP inhibition and facilitating a successful partnership with Boehringer Ingelheim. Our experience with the team has been professional, enjoyable, and resulted in fruitful outcomes.

opnMe has significantly advanced our research on the therapeutic potential of SOS1 deletion or inhibition in KRAS-driven and other RAS-dependent malignancies. By providing access to critical compounds, opnMe has enabled us to conduct studies that assess safety and efficacy of single and dual SOS1/SOS2 inhibition.